SCHEMBL16446816

SCHEMBL16446816

CCc1nc(-c2ccc(OC)c(F)c2)nc2[nH]ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ PDE4B Q07343 4/20 0.46
▸ NPC1 O15118 4/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ CYP17A1 P05093 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ABCG2 Q9UNQ0 2/20 0.38
▸ HTT P42858 1/20 0.37
▸ TRPA1 O75762 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ TGFBR2 P37173 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16447012 0.84 ALDH1A1 (0.44) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL16446820 0.72 PDE4B (0.53) ALDH1A1KDM4EMAPTPDE4BNPC1
SCHEMBL30611601 0.68 TRPA1 (0.42) TRPA1TGFBR1TGFBR2AURKADAPK3
SCHEMBL16448282 0.68 PDE4B (0.64) PDE4BRAB9ALMNAHTTJAK2
SCHEMBL16446529 0.68 PDE4B (0.47) ALDH1A1KDM4EMAPTPDE4BNPC1
SCHEMBL5031343 0.68 RAB9A (0.57) ALDH1A1KDM4EMAPTNPC1RAB9A
SCHEMBL23147921 0.67 BRD4 (0.43) PDGFRBTRPA1TGFBR1TGFBR2KIT
SCHEMBL29721888 0.67 BRD4 (0.43) PDGFRBTRPA1TGFBR1TGFBR2KIT
SCHEMBL13828608 0.67 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTPDE4BNPC1
SCHEMBL16446457 0.67 TRPA1 (0.42) ALDH1A1KDM4EMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP ALDH1A1 462/4885KDM4E 1607/4885MAPT 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback